Glass Ionomer
PreclinicalSmall molecule
Glass Ionomer is one of 25 small molecule programs targeting Pediatric. It is currently in Preclinical.
1
Indications
5
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
33 competitors in Pediatric
#DrugCompanyPhaseTrials
1Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Oxycontin
PProtega
Approved
Siliq
BBausch Health Americas, Inc.
Approved
Blincyto
AmgenPhase 3
Venclexta
AbbViePhase 3
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Luye
Ascentage Pharma Group Inc.Phase 3
Homoharringtonine
Ascentage Pharma Group Inc.Phase 3
Fycompa
CCatalyst Biosciences
Phase 2
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Silver Diamine Fluoride2 trials
Treatment of Primary Molars With Deep Caries Using Silver Diamine Fluoride
Unknown status·—·Phase 4·NCT03563534·20 enrolled
Silver Diamine Fluoride After Minimal Caries Removal Technique in Asymptomatic Young Permanent Teeth With Deep Caries
Unknown status·—·Phase 4·NCT03568474·40 enrolled
OSA1 trial
Antibacterial Effect and Clinical Performance of Chitosan Modified Glass Ionomer
Completed·—·Phase 3·NCT04365270·65 enrolled
Treatment1 trial
Evaluation of Biodentine Versus Glass Ionomer Cement in Treatment of Very Deep Carious Lesions
Completed·—·Phase 3·NCT02868918·120 enrolled
Pediatric1 trial
Evaluation of Different Cementation Materials Used in Prefabricated Pediatric Zirconia Crowns
Active, not recruiting·—·N/A·NCT06690229·36 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Glass Ionomer. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- CCairo University